ENA Respiratory

ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051

10 February 2025 -- Melbourne, Australia -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence immune enhancers to minimize the impact of viral respiratory infections, announces today it has received a US$5 million investment from Flu Lab. Flu Lab, a California-based organization founded to advance innovative approaches for the prevention and treatment of...

ENA Respiratory Successfully Completes Phase Ib Dosing of Antiviral Host Defense Immune Enhancer INNA-051 Dry Powder Formulation in Older Adults and Advances Study in Young Adults  

New intranasal formulation with significantly improved stability was well-tolerated and led to local activation of innate immune pathways in adults aged >60 U.S. Department of Defense (DOD) funded study extension into younger adults aged 18 – 45 will complete dosing in January  22 January 2025 – Melbourne, Australia – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host...